{"title":"Patient with Refractory Epilepsy Associated with Oligondendroglioma","authors":"Mauricio Vaillant Amarante, Ozinelia Pedroni Batista, Camilia Lampier Lutzke, Shirley Kempin Quiqui","doi":"10.11648/J.CNN.20190302.13","DOIUrl":null,"url":null,"abstract":"Oligodendroglioma is a rare form of primary brain tumor, accounting for about 2-5% of intracranial tumors, being more common in adult males but rare in children, accounting for about 1-2% of all primary brain tumors in children. It originates from oligodendrocytes or glial precursor cells and exhibits infiltrative and slow growth. They can be classified in two grades (Grade II and Grade III), where Grade II are low grade tumors and have tumor cells that grow slowly and invade nearby normal tissue, and Grade III are malignant and have rapidly growing tumors. It has low growth and 50-80% of cases first symptom is seizures. A seizure is a symptom that requires a rapid solution usually requiring empirical treatment at the initial time to cease seizures and promote some well-being for the patient's routine. Seizures can cause a lot of damage to the patient's life, especially if the patient is a child who does not know what to do and what to do. Depending on the intensity and frequency of seizure episodes, the patient may experience fractures with falls, may suffer discrimination and prejudice at school. The causes behind refractory epilepsy are diverse, so whenever a patient is found to be refractory to drug treatment, the origin of seizures should be investigated early, it is not enough to stop at empirical treatment.","PeriodicalId":93199,"journal":{"name":"Journal of clinical neurology and neuroscience","volume":"36 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical neurology and neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11648/J.CNN.20190302.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Oligodendroglioma is a rare form of primary brain tumor, accounting for about 2-5% of intracranial tumors, being more common in adult males but rare in children, accounting for about 1-2% of all primary brain tumors in children. It originates from oligodendrocytes or glial precursor cells and exhibits infiltrative and slow growth. They can be classified in two grades (Grade II and Grade III), where Grade II are low grade tumors and have tumor cells that grow slowly and invade nearby normal tissue, and Grade III are malignant and have rapidly growing tumors. It has low growth and 50-80% of cases first symptom is seizures. A seizure is a symptom that requires a rapid solution usually requiring empirical treatment at the initial time to cease seizures and promote some well-being for the patient's routine. Seizures can cause a lot of damage to the patient's life, especially if the patient is a child who does not know what to do and what to do. Depending on the intensity and frequency of seizure episodes, the patient may experience fractures with falls, may suffer discrimination and prejudice at school. The causes behind refractory epilepsy are diverse, so whenever a patient is found to be refractory to drug treatment, the origin of seizures should be investigated early, it is not enough to stop at empirical treatment.